NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
Bayer
Fundacion Clinic per a la Recerca Biomédica
Bayer
Asan Medical Center
Bayer